arexvy rsv - Search News

News

GSK, RSV and European Medicines Agency

GSK applies to EU regulator for expanded use of RSV vaccine

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults below the age of 50 who are at risk of the disease, the British drugmaker said on Friday.

Medical Dialogues · 11h

GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older

· 1d

GSK (LSE:GSK) Seeks European Expansion Of RSV Vaccine To Adults 18 And Older

FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

Pharmabiz1d

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older: London, UK Saturday, June 14, 2025, 10:00 Hrs [IST] GSK plc announced tha ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

News

GSK, RSV and European Medicines Agency

Trending now